Related Experiment Video
Updated: May 16, 2025
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Chenodeoxycholic Acid-Mediated neuroprotection via α-synuclein and BDNF Modulation in MPTP-Induced mouse model of
Mehwish Mehreen1, Mehak Ali1, Huraira Tariq1
1Department of Biomedical Engineering and Sciences, School of Mechanical and Manufacturing Engineering, National University of Sciences and Technology, H-12, 44000 Islamabad, Pakistan.
Abstract:
Parkinson's disease (PD) remains a major challenge in the field of neurodegenerative diseases and requires innovative therapeutic approaches. In this study, we investigated the therapeutic potential of chenodeoxycholic acid (CDCA) in PD using a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model. CDCA, a naturally occurring bile acid, has previously shown promise in various neurological disorders by reducing neuronal degeneration and promoting neuronal health, however its utility in PD has not been studied. We divided mice into a control group, an MPTP-induced PD model and a treatment group injected with CDCA. CDCA reduced motor impairment and ameliorated anxiety-like behavior as assessed through the pole and open field test, demonstrated antidepressant effects in the forced swim and tail suspension test, and results of the Y-maze test showed improved cognitive performance. Furthermore, the effective defense against MPTP-induced dopaminergic degeneration was provided by CDCA by improving the morphological and histological features of neurons in the midbrain, hippocampus, cortex and cerebellum. Analysis via RT-PCR revealed that CDCA significantly mitigated MPP + -induced elevations in α-synuclein levels, indicating its potential to preserve neuronal function by modulating synaptic integrity. Additionally, CDCA effectively reduced the associated toxicity by enhancing the low levels of brain-derived neurotrophic factor. Conclusively, given the increasing prevalence of PD and the urgent need for effective neuroprotective strategies, our findings suggest that CDCA exerts neuroprotective effects in an MPTP-induced PD model. These results highlight CDCA as a promising candidate for further investigation in PD therapy and provide a basis for further research into bile acid-based treatments in neurodegenerative diseases.
Insights
Chenodeoxycholic acid (CDCA) shows neuroprotective effects in a Parkinson's disease (PD) mouse model. This bile acid improved motor function, cognition, and neuronal health, offering a promising therapeutic avenue for PD.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Parkinson's disease (PD) is a challenging neurodegenerative disorder with unmet therapeutic needs.
- Chenodeoxycholic acid (CDCA), a natural bile acid, has demonstrated neuroprotective properties in other neurological conditions.
- The potential of CDCA in PD has not been previously investigated.
Purpose of the Study:
- To evaluate the therapeutic efficacy of CDCA in a mouse model of Parkinson's disease.
- To assess CDCA's impact on motor deficits, anxiety, depression, and cognitive function in PD models.
- To investigate CDCA's neuroprotective mechanisms against dopaminergic degeneration and associated pathologies.
Main Methods:
- Establishment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD.
- Administration of CDCA to MPTP-treated mice and assessment of behavioral outcomes (pole test, open field test, forced swim test, tail suspension test, Y-maze test).
- Histological and morphological analysis of neuronal integrity in key brain regions; RT-PCR analysis of alpha-synuclein and brain-derived neurotrophic factor (BDNF) levels.
Main Results:
- CDCA treatment significantly ameliorated motor impairments, anxiety-like behaviors, and depressive symptoms in the PD model.
- Improved cognitive performance was observed in CDCA-treated mice as evidenced by Y-maze test results.
- CDCA protected against MPTP-induced dopaminergic neurodegeneration, improved neuronal morphology, reduced alpha-synuclein levels, and enhanced BDNF expression.
Conclusions:
- CDCA demonstrates significant neuroprotective effects in an MPTP-induced PD mouse model.
- CDCA alleviates motor deficits and cognitive impairments while preserving dopaminergic neurons.
- These findings position CDCA as a promising therapeutic candidate for Parkinson's disease and suggest further research into bile acid-based neuroprotective strategies.
More Related Videos
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:15Parkinson's Disease: Overview